blonanserin

a dopamine-D2 and serotonin-S2 antagonist

Also Known As:

2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; AD 5423; AD-5423; AD5423; cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-; lonasen

Networked: 121 relevant articles (33 outcomes, 48 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - blonanserin: 121
  - Piperidines: 17
    - blonanserin: 121

Experts

1.	Iwata, Nakao: 13 articles (01/2022 - 02/2013)
2.	Nakamura, Hiroshi: 12 articles (01/2022 - 12/2008)
3.	Kishi, Taro: 10 articles (01/2022 - 02/2013)
4.	Matsuda, Yuki: 8 articles (04/2020 - 02/2013)
5.	Ishigooka, Jun: 6 articles (01/2022 - 10/2013)
6.	Okubo, Yoshiro: 5 articles (05/2022 - 04/2013)
7.	Tateno, Amane: 5 articles (05/2022 - 04/2013)
8.	Miyamoto, Seiya: 5 articles (01/2017 - 01/2012)
9.	Tenjin, Tomomi: 5 articles (01/2017 - 01/2012)
10.	Takaki, Manabu: 5 articles (06/2015 - 12/2012)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2019 - "These findings also provide in vivo evidence that blonanserin antagonism of the dopamine-D3 receptors may be useful as a novel treatment strategy and that the dopamine-D3 receptors can be a novel therapeutic target molecule for the social deficit observed in schizophrenia." 12/01/2014 - "Blonanserin was well tolerated and effective for the treatment of first-episode schizophrenia in terms of subjective wellness, cognition, and a wide range of pathological symptoms. " 02/10/2003 - "These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia." 01/01/2020 - "Blonanserin transdermal patches are safe and effective in the long-term treatment of schizophrenia. " 10/01/2015 - "Thus, blonanserin is useful for the treatment of Chinese schizophrenia patients. "
2.	Delirium 06/01/2011 - "Blonanserin may be effective and safe in the treatment of delirium in the ICU." 04/01/2013 - "Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study." 06/01/2011 - "The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). " 06/01/2011 - "Blonanserin in the treatment of delirium." 10/01/2010 - "Case of delirium complicated with pneumonia that improved with blonanserin administration."
3.	Hyperprolactinemia 01/01/2010 - "Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. " 10/01/2015 - "Therefore, while a rate of PRL rising is low to moderate, hyperprolactinemia is a considerable adverse effect in the blonanserin treatment. " 10/01/2015 - "Based on our findings, we conclude that low dose blonanserin medication may be useful for schizophrenia maintenance treatment without hyperprolactinemia and a high rate of relapse. " 01/01/2013 - "Successful treatment with blonanserin for drug-induced hyperprolactinemia in chronic schizophrenia patients: a six-month follow-up of two cases." 04/01/2013 - "The clinical implications obtained in this study were the optimal therapeutic dose range of 12.9 to 22.1 mg/d of blonanserin required for 70% to 80% dopamine D(2) receptor occupancy in the striatum, and the good blood-brain barrier permeability that suggested a relatively lower risk of hyperprolactinemia."
4.	Psychotic Disorders (Schizoaffective Disorder) 12/01/2013 - "Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases." 01/01/2016 - "In both the cases presented, symptoms of psychosis were improved by switching medications from other antipsychotic drugs to blonanserin. " 01/01/2016 - "We report two cases of MA-induced psychosis (MAP) in patients with ID who were treated with the antipsychotic blonanserin. " 12/01/2013 - "We report two outpatients, one with schizophrenia and one with schizoaffective disorder, who developed manic or hypomanic episodes following the initiation of blonanserin during the course of treatment. " 11/01/1998 - "AD-5423, a D(2)/5-HT2 antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other psychoses. "
5.	Dementia (Dementias) 06/01/2015 - "Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. " 12/01/2010 - "The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). " 06/01/2015 - "Effect and tolerability of blonanserin in severe delusion with various types of dementia." 12/01/2010 - "Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin."

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Risperidone (Risperdal Consta)
3.	Haloperidol (Haldol)
4.	Prolactin
5.	Tablets
6.	Dopamine D3 Receptors
7.	Phencyclidine (Angel Dust)
8.	Dopamine (Intropin)
9.	Aripiprazole (Abilify)
10.	Dopamine D2 Receptors (Dopamine D2 Receptor)

Related Therapies and Procedures

1.	Transdermal Patch
2.	Therapeutics
3.	Polypharmacy
4.	Drug Tapering